Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Pennsylvania |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000355 |
The purpose of this study is to evaluate the behavioral and physiological effects of buprenorphine and naloxone, both alone and in combination.
Condition | Intervention | Phase |
---|---|---|
Opioid-Related Disorders Substance-Related Disorders |
Drug: Buprenorphine |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Effects of Buprenophine and Naloxone in Opiate Addicts |
Ages Eligible for Study: | 21 Years to 59 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Pennsylvania | |
University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 6178 |
Principal Investigator: | Charles O'Brien, M.D., Ph.D. | PDVAMC Treatment Research Center |
Study ID Numbers: | NIDA-3-0012-4, Y01-3-0012-4 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000355 |
Health Authority: | United States: Federal Government |
Buprenorphine Mental Disorders Substance-Related Disorders |
Disorders of Environmental Origin Opioid-Related Disorders Naloxone |
Disease Physiological Effects of Drugs Narcotic Antagonists Central Nervous System Depressants Narcotics Pharmacologic Actions Pathologic Processes |
Sensory System Agents Therapeutic Uses Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid |